



Date: 28<sup>th</sup> May, 2021.

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir,

Ref : Script Id "BAJAJHCARE", Script Code "539872".  
Sub : Business Updates- Launch of Posaconazole API, the commonly used for treating Mucormycosis (Black fungus) infections in Covid-19 patients.

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - Launch of "Posaconazole API", the commonly used for treating Mucormycosis (Black fungus) infections in Covid-19 patients.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of  
Bajaj Healthcare Limited

Aakash Kesari  
Company Secretary

**BAJAJ HEALTHCARE LIMITED**

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : [www.bajajhealth.com](http://www.bajajhealth.com)

CIN NO.: L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1,  
Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

---

### **BHL launched “Posaconazole API”, the commonly used for treating Mucormycosis (Black fungus) infections in Covid-19 patients.**

**Thane, 28<sup>th</sup> May 2021:** Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced the launch of **“Posaconazole API” used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients**. BHL has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market **“Posaconazole API”** as approved medication for treating Mucormycosis in India and it will commence its commercial production from 1<sup>st</sup> week of June 2021.

Posaconazole is a triazole antifungal agent indicated for treating **Mucormycosis** patients popularly known as **Black Fungus** in post Covid complications. Black fungus is a deadly fungal infection and has triggered a new health challenge in the country. More than 11,000 cases of black fungal infection have been reported from different parts, forcing state governments to declare it an epidemic.

*Source; May 27,2021- Article of Times of India.*

**Commenting on the launch of “Posaconazole API”, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said** *“We are pleased to add Posaconazole API to our growing product portfolios. The second waves of coronavirus is more aggressive and bigger in number than the first According to Doctors the fungal infection that has emerged during the second wave has been widely linked with excessive usage of steroids and uncontrolled diabetes in coronavirus positive patients. We hope the availability of an effective treatment such as Posaconazole will considerably ease the pressure and offer patients much needed and timely therapy option.”*

BHL has successfully developed the active pharmaceutical ingredient (API) for Posaconazole through its own in-house R&D team. The drug will be available as a prescription-based medication, with recommended doses.

The FDA Gandhi Nagar, Gujarat (India) has granted permissions to manufacture and market the **“Posaconazole API”** in the domestic as well as overseas market.

### **About Bajaj Healthcare Limited**

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

---

*For further information on the Company, please visit [www.bajajhealth.com](http://www.bajajhealth.com)*

Rupesh Nikam (CFO)

**Bajaj Healthcare Limited**

Contact: +91 22 6617 7400

Email: [investors@bajajhealth.com](mailto:investors@bajajhealth.com)

Krunal Shah/ Vinayak Shirodkar

**Captive IR Strategic Advisors Pvt. Ltd.**

Contact: +91 98922 88895

Email: [krunal@cap-ir.com](mailto:krunal@cap-ir.com) / [Vinayak@cap-ir.com](mailto:Vinayak@cap-ir.com)

**Disclaimer:**

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE